Valentina Capo

Researcher

Area of interest:

Valentina Capo is a researcher (III level) at the National Research Council (CNR) Institute for Genetic and Biomedical Research (IRGB), Milan Unit, and a post-doctoral fellow at San Raffaele Institute for Gene Therapy (SR-Tiget). Her main research interest is the lentiviral vector gene therapy for osteopetrosis and primary immunodeficiencies.

She graduated in Human Biology and Evolution at University of Rome “Tor Vergata”, where she also received her PhD on Immunology and Applied Biotechnology. PhD work focused on development of dual regulated lentiviral vector for the gene therapy of chronic granulomatous disease, under the supervision of Prof. Alessandro Aiuti. As a post-doc, she moved at SR-Tiget in Dr. Anna Villa’s lab, to develop lentiviral vector gene therapy for Omenn Syndrome and for autosomal recessive osteopetrosis. Additional interests include the study of pathophysiology of primary immunodeficiency and their autoimmune manifestations. In 2019, she was awarded a fellowship from the European Calcified Tissue Society to study non-genotoxic conditioning for osteopetrosis. In 2020, she obtained a permanent position as Researcher at IRGB-CNR.

Most significant publications:

2021

Capo, V; Penna, S; Merelli, I; Barcella, M; Scala, S; Basso-Ricci, L; Draghici, E; Palagano, E; Zonari, E; Desantis, G; Uva, P; Cusano, R; Sergi, L Sergi; Crisafulli, L; Moshous, D; Stepensky, P; Drabko, K; Kaya, Z; Unal, E; Gezdirici, A; Menna, G; Serafini, M; Aiuti, A; Locatelli, S L; Carlo-Stella, C; Schulz, A S; Ficara, F; Sobacchi, C; Gentner, B; Villa, A

Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of ŦCIRG1 osteopetrosis Journal Article

In: Haematologica, 106 (1), pp. 74–86, 2021.

BibTeX

2018

Capo, V; Castiello, M C; Fontana, E; Penna, S; Bosticardo, M; Draghici, E; Poliani, L P; Sergi, L Sergi; Rigoni, R; Cassani, B; Zanussi, M; Carrera, P; Uva, P; Dobbs, K; Sacchetti, N; Notarangelo, L D; van Til, N P; Wagemaker, G; Villa, A

Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation Journal Article

In: J Allergy Clin Immunol, 142 (3), pp. 928–941, 2018.

BibTeX

2017

Schiroli, G; Ferrari, S; Conway, A; Jacob, A; Capo, V; Albano, L; Plati, T; Castiello, M C; Sanvito, F; Gennery, A R; Bovolenta, C; Palchaudhuri, R; Scadden, D T; Holmes, M C; Villa, A; Sitia, G; Lombardo, A; Genovese, P; Naldini, L

Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCIĐ-X1 Journal Article

In: Sci Transl Med, 9 (411), 2017.

BibTeX

2014

Chiriaco, M; Farinelli, G; Capo, V; Zonari, E; Scaramuzza, S; Matteo, G Di; Sergi, L S; Migliavacca, M; Hernandez, R J; Bombelli, F; Giorda, E; Kajaste-Rudnitski, A; Trono, D; Grez, M; Rossi, P; Finocchi, A; Naldini, L; Gentner, B; Aiuti, A

Đual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis Journal Article

In: Mol Ther, 22 (8), pp. 1472–1483, 2014.

BibTeX